Brookmont Capital Management Has $3.67 Million Stock Position in AstraZeneca PLC (NASDAQ:AZN)

Brookmont Capital Management lifted its holdings in AstraZeneca PLC (NASDAQ:AZN - Free Report) by 54.8% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 55,985 shares of the company's stock after purchasing an additional 19,827 shares during the period. AstraZeneca comprises 2.0% of Brookmont Capital Management's holdings, making the stock its 17th biggest holding. Brookmont Capital Management's holdings in AstraZeneca were worth $3,668,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Stratos Wealth Advisors LLC raised its holdings in shares of AstraZeneca by 2.0% during the third quarter. Stratos Wealth Advisors LLC now owns 6,699 shares of the company's stock valued at $522,000 after acquiring an additional 133 shares during the period. Crumly & Associates Inc. raised its stake in AstraZeneca by 2.2% during the 3rd quarter. Crumly & Associates Inc. now owns 6,644 shares of the company's stock valued at $518,000 after purchasing an additional 143 shares during the period. Diversify Wealth Management LLC lifted its holdings in shares of AstraZeneca by 3.6% in the fourth quarter. Diversify Wealth Management LLC now owns 4,402 shares of the company's stock valued at $295,000 after purchasing an additional 153 shares in the last quarter. Veery Capital LLC boosted its position in shares of AstraZeneca by 4.7% in the fourth quarter. Veery Capital LLC now owns 3,503 shares of the company's stock worth $230,000 after buying an additional 157 shares during the period. Finally, Harbour Investments Inc. grew its holdings in shares of AstraZeneca by 1.9% during the third quarter. Harbour Investments Inc. now owns 8,805 shares of the company's stock valued at $686,000 after buying an additional 160 shares in the last quarter. 20.35% of the stock is currently owned by institutional investors.

AstraZeneca Stock Performance

AstraZeneca stock traded up $1.36 during trading hours on Tuesday, hitting $67.96. The stock had a trading volume of 5,478,626 shares, compared to its average volume of 4,986,170. AstraZeneca PLC has a fifty-two week low of $60.47 and a fifty-two week high of $87.68. The company has a market cap of $210.75 billion, a PE ratio of 32.52, a price-to-earnings-growth ratio of 1.04 and a beta of 0.46. The company has a 50-day moving average of $66.14 and a two-hundred day moving average of $74.39. The company has a quick ratio of 0.71, a current ratio of 0.93 and a debt-to-equity ratio of 0.71.

AstraZeneca (NASDAQ:AZN - Get Free Report) last announced its quarterly earnings results on Tuesday, November 12th. The company reported $1.04 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.01 by $0.03. AstraZeneca had a net margin of 12.68% and a return on equity of 30.01%. The firm had revenue of $13.57 billion for the quarter, compared to analyst estimates of $13.08 billion. During the same quarter in the previous year, the firm posted $0.87 EPS. The business's revenue for the quarter was up 18.0% on a year-over-year basis. On average, equities research analysts anticipate that AstraZeneca PLC will post 4.11 EPS for the current fiscal year.

Analyst Ratings Changes

Several analysts recently commented on the stock. Deutsche Bank Aktiengesellschaft upgraded shares of AstraZeneca from a "sell" rating to a "hold" rating in a report on Wednesday, November 6th. UBS Group upgraded shares of AstraZeneca from a "sell" rating to a "neutral" rating in a report on Wednesday, November 20th. Two investment analysts have rated the stock with a hold rating, six have issued a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and a consensus price target of $89.75.

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.